Eloxx Pharmaceuticals, Inc. (ELOX) Stock Score, Valuation & Financial Research

Eloxx Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ELOX

Eloxx Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 15.31. These figures are a research snapshot, not a buy or sell recommendation.

What Eloxx Pharmaceuticals, Inc. does

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule product candidates designed to modulate the ribosome. The company aims to promote readthrough of premature stop codons caused by nonsense mutations to enable the production of full-length proteins for the treatment of rare genetic diseases.

Products and services

  • The company's primary product candidate is exaluren, which is being developed for the treatment of various genetic conditions including Angelman syndrome, cystic fibrosis, MPS I, Rett syndrome, and cystinosis.

Customer types

Clinical trial sites.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct and manage its clinical trials. Source

Business strengths to evaluate

  • Orphan Drug Designation for lead candidate exaluren across multiple indications Source

Business risks and research considerations

  • History of operating losses and requirement for additional capital to fund operations Source
  • Clinical trial failure or delays and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ELOX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 15.31
Market capitalization:
52.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -13.56M
Free cash flow:
USD 0.00
Cash:
USD 61.96M
Total debt:
USD 1M
EPS:
USD -20.85

What stands out

  • Free cash flow is USD 0.00, zero for the stored period.
  • The balance sheet shows USD 61.96M of cash versus USD 1M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 60.96M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ELOX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Why is ELOX's stored free cash flow zero, and do the filing and calculation confirm that value?
  • How is ELOX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ELOX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ELOX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ELOX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.